59 results about "Chemotherapy resistant" patented technology

The invention discloses a sulfatase-driven polypeptide condensate with a chemotherapy sensitization effect and a preparation method thereof, and belongs to the field of biological medicines. According to the principle that sulfatase can catalyze hydrolysis of sulfate bonds, main polypeptide YSO4F responded by sulfatase enzyme is designed and synthesized; and the enzyme response aggregate m-YSO4F-LSG is blended with a protein G3BP2 ligand FGDF-YSO4F to prepare the enzyme response aggregate m-YSO4F-LSG with a sorafenib chemosensitization effect. Tumor cells can generate stress particles with a chemotherapy drug resistance effect under the stimulation of a chemotherapy drug sorafenib, the treatment effect of the sorafenib is weakened, and the protein G3BP2 is one of core proteins of the stress particles. After the m-YSO4F-LSG enters tumor cells, sulfate groups are hydrolyzed under the catalytic action of sulfatase overexpressed in tumor cell lysosomes, so that phase separation liquid drops d-YF-LSG with high affinity to protein G3BP2 are formed in the cells in situ, the phase separation liquid drops d-YF-LSG act with the protein G3BP2 and are fused with stress particles, chemotherapy drug resistance generated by the stress particles is inhibited, and the chemotherapy effect is improved. The treatment effect is improved.

The invention discloses a lipidosome drug delivery system for targeted therapy of brain glioma and application thereof. The lipidosome drug delivery system is a lipidosome mixture prepared from a basic component, a functional component and an external water-phase buffer solution. After intravenous injection, the liposome is efficiently combined with complement protein C3 and immune globulin M in plasma to synergistically activate a complement system, actively attracts and activates neutrophils to uptake, and crosses a blood brain barrier in a mode of'building a defecation vehicle 'by utilizing the inflammatory taxis of the neutrophils. Neutrophile granulocytes are stimulated by inflammatory factors in a microenvironment after reaching a tumor brain area to form extracellular trap release lipidosome. The lipidosome realizes specific targeting through folate receptors over-expressed on the surfaces of glioma cells. The liposome shows excellent cross-blood-brain-barrier drug delivery efficiency and brain glioma curative effect in vivo, can be effectively combined with surgery, radiotherapy and the like, and provides a solution for the main problems of radiotherapy resistance, chemotherapy drug resistance and the like in clinic.

The application provides a preparation method of NK cell-derived nanovesicles and application thereof. Specifically, the application provides NK cell-derived nanovesicles (NK-NVs) which are similar to the characteristics and functions of NK cell-derived extracellular vesicles by an extrusion method / stress gradient membrane remodeling technology, and also provides a drug composition, a drug delivery system and corresponding use of the NK-NVs as a delivery carrier for delivering an antitumor drug. The preparation method of the application can mass-produce NK-NVs and kill various types of tumor cells. The NK-NVs have multiple advantages in drug delivery, so that they are expected to be a new choice for tumor immunotherapy, especially for tumor cells with drug resistance, and can significantly improve the sensitivity to chemotherapeutic drugs, and have a wide application prospect.

The invention belongs to the technical field of biomedicine, and relates to a human bladder cancer cell line ZSZB1 with primary cis-platinum drug resistance and application thereof. The cell line is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC No: C2024120, and the cell line is derived from a radical operation specimen of primary chemotherapy drug-resistant bladder cancer patients of Chinese population, and has stable in-vitro multiplication capacity and primary cis-platinum drug-resistant characteristic. The ZSZB1 provides an ideal experimental model for bladder cancer pathogenesis research, cis-platinum drug resistance mechanism exploration and novel antitumor drug screening. Establishment of the cell line can effectively promote transformation from basic research of bladder cancer to clinical application, and the cell line is of great significance to promotion of precise medical development.

The application provides a reduction-responsive nano delivery system and application thereof in preparation of a drug for treating drug-resistant tumors, and belongs to the pharmaceutical field. The application constructs a reduction-responsive branched copolymer functionalized by pegylation and deoxycholic acid (DA) (referred to as: pegylated branched poly(HPMA-DA)), which can effectively encapsulate small molecule drugs to form a nano delivery system. Experiments prove that the nano delivery system can be taken up by tumor cells, has good tumor targeting, and exhibits excellent anti-tumor effect in tumor xenografts (CDX) derived from non-small cell lung cancer (NSCLC) chemoresistant cell lines and patient-derived xenograft mouse models (PDX). The pegylated branched poly(HPMA-DA) provided by the application has wide application prospect in preparation of a drug carrier, and the nano delivery system provided by the application has wide application prospect in preparation of a drug for treating cancer.

The invention discloses a nucleolin aptamer modified carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system as well as a preparation method and application thereof, and relates to the field of tumor treatment. The nucleolin aptamer AS1411 is coupled with glycolysis regulation nano-particles through covalent bonds, and the carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system comprises a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system, a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system and a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system, the glycolysis regulation nano-particles take carboxymethyl chitosan as a carrier skeleton, the carrier skeleton is loaded with a lonidamine derivative through grafting modification, and the nano drug delivery system can synchronously entrap paclitaxel. According to the invention, a synergistic treatment system integrating active targeting, metabolic regulation and chemotherapy is constructed, and by virtue of a multi-mechanism synergistic effect, an antitumor drug for inhibiting tumor cell activity, glycolysis or tumor metabolism reprogramming is prepared; the huge potentials of overcoming the drug resistance bottleneck of traditional chemotherapy, enhancing the curative effect and reducing the toxic and side effects are shown.

Provided are a human NBS1 protein antigen lactylated at lysine 388, an antibody, a preparation method therefor, and a use thereof, relating to the technical field of biomedicine. A human NBS1 protein antigen peptide lactylated at lysine 388 is provided, and is used to prepare an antibody targeting lactylation at lysine 388 of human NBS1 protein. The antibody targeting lactylation at lysine 388 of human NBS1 protein can detect expression differences among normal cells, tumor cells, and drug-treated tumor cells, thereby helping to study the role of lactylation modification of human NBS1 protein in the occurrence and development of tumor diseases, and providing potential therapeutic targets for clinical diagnosis or treatment of tumor diseases. The antibody targeting lactylation at lysine 388 of human NBS1 protein can be used to detect the lactylation level of human NBS1 protein, and to investigate its relationship with tumor diagnosis and resistance to radiotherapy and chemotherapy, thereby offering broad clinical application prospects in disease diagnosis, treatment, and prognosis evaluation.

A lactylated NBS1 protein and uses thereof. A lactylation site is lysine 388 of an NBS1 protein. Lactylation at the K388 site of the NBS1 protein activates a DNA repair pathway, and enables various uses including promoting drug resistance of tumor cells in radiotherapy and chemotherapy and enhancing DNA homologous recombination repair. By means of targeted inhibition of the lactylated NBS1 protein, drug resistance of tumors in radiotherapy or chemotherapy can be reversed, providing a potential target for reversing drug resistance of tumors in radiotherapy or chemotherapy.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

This invention belongs to the field of molecular biology technology, specifically involving tRF5-22-SeCTCA-1, tRF5-22-SeCTCA-1 detection reagents, kits, and their applications. This invention discovers and verifies that tRF5-22-SeCTCA-1 plays a key regulatory role in the process of 5-fluorouracil (5-FU) chemotherapy resistance in colorectal cancer, filling a gap in the research of tRNA-derived fragments (tRFs) in colorectal cancer chemotherapy resistance. It is the first tRF molecule reported to be associated with 5-FU chemotherapy resistance in colorectal cancer, providing a novel molecular target and research direction for predicting chemotherapy resistance in colorectal cancer. This invention also provides a therapeutic strategy targeting tRF5-22-SeCTCA-1 and establishes α-ketoglutarate as an independent reversal agent, providing multi-dimensional technical solutions for the precision diagnosis and treatment of colorectal cancer and the reversal of chemotherapy resistance.

A preparation method of a tumor microparticle encapsulating a metabolic inhibitor includes following steps. A tumor cell is cultivated, and a statin drug is added to a culture medium after the tumor cell grows stably. Then, the tumor cell is irradiated with an ultraviolet, and then the tumor cell is incubated in a cell incubator for 22˜26 hours. After the incubation, cell supernatant is collected and the tumor microparticle encapsulating the metabolic inhibitor is obtained through a gradient centrifugation. The preparation method uses tumor cell-derived microparticles as drug delivery platforms, with a simple preparation process that preserves functions such as biosafety, biocompatibility, targeting, and intercellular communication. The preparation method discovers new uses of a statin drug, which can inhibit tumor growths with the statin drug, regulate tumors metabolism and improve a tumor microenvironment, and have a potential to enhance a chemotherapy efficacy and delay a chemotherapy resistance.

The invention belongs to the technical field of biological medicines, and discloses application of a CCT6A inhibitor in preparation of a medicine for treating colorectal cancer. CCT6A is determined to be a key cancer promoting gene of colorectal cancer for the first time, the CCT6A is remarkably and highly expressed in colorectal cancer tissues and cell lines, and high expression indicates poor prognosis of patients, so that a brand-new specific target is provided for targeted therapy of colorectal cancer. The invention discloses the cancer promoting effect of the compound in colorectal cancer and the association with 5FU drug resistance for the first time, enriches the development of colorectal cancer and the molecular mechanism research of chemotherapy drug resistance, and provides a new theoretical basis and research direction for the fundamental research in the field. Experiments prove that the inhibitor can significantly reduce the mRNA level of CCT6A in colorectal cancer cells so as to strongly inhibit tumor cell proliferation and increase the sensitivity of the colorectal cancer cells to 5-FU, and a novel therapeutic drug with high specificity and high curative effect is provided for treatment of colorectal cancer.

The invention discloses a method for capturing, identifying and culturing circulating tumor cells of sarcoma in vitro. The method comprises a step of filtering a peripheral blood sample of a sarcoma patient by using a flexible microfiltration membrane, and cells obtained by filtration can be directly subjected to multiplication culture on the filtration membrane. Immunomagnetic beads of a monoclonal antibody combination group coupled with the anti-human leukocyte surface antigen CD45 can be used for negative enrichment and then multiplication culture is carried out in a cell culture bottle, and the captured or cultured cells can be subjected to subtype identification, characterization and counting by adopting an iFISH technology. It is found for the first time that the flexible microfiltration membrane can be used for capturing and culturing the sarcoma circulating tumor cells, and the flexible microfiltration membrane has no toxic effect on the sarcoma circulating tumor cells. The invention not only provides an effective means for real-time monitoring of relapse and metastasis processes of sarcoma patients and chemotherapy drug resistance monitoring, but also can perform drug sensitivity experimental verification on CTC after multiplication culture, and provides a powerful weapon for accurate diagnosis and treatment of sarcoma.

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

The invention discloses an application of brucein D and Vinetoram in preparation of a medicine for treating acute or drug-resistant myelogenous leukemia. Through a large number of experimental screening, the brucein D and the Venotocork are combined for medication, and the test result shows that the brucein D and the Venotocork act on different targets and different signal channels of AML cells to generate a remarkable synergistic anti-tumor effect, and after the brucein D and the Venotocork are combined, the proliferation inhibition and apoptosis induction effects on the AML cells can be directly enhanced, and the anti-tumor effect of the Venotocork D and the AML cells can be improved. The compound can also reverse the drug resistance possibly occurring when the Vinetoram is singly used, and also has a remarkable killing effect on chemotherapy drug-resistant AML cells at the same time. The composition provided by the invention can reduce the dosage of antitumor drugs, reduce drug resistance, reduce adverse reactions and improve the life quality of patients, and has important application prospects.

The invention relates to a 3, 4, 5-trihydroxy phenylacetate compound and a preparation method and application thereof, the 3, 4, 5-trihydroxy phenylacetate compound belongs to a compound shown in a general formula I and a general formula II, R1, R2 and corresponding derivatives thereof can activate a copper death pathway mediated by endogenous copper ions, have an obvious anti-tumor effect, and have a stronger anti-tumor effect in chemotherapy of drug-resistant tumors. The tumors comprise melanoma, liver cancer, gastric cancer, breast cancer, oral squamous cell carcinoma and the like. The compound is a non-copper ion carrier compound with a brand new structure, induced copper death does not depend on exogenous copper ions, and endogenous copper ions are dissociated by reducing the content of glutathione which is a copper ion chelate in cells. The copper ions are further combined with microfilament skeleton related protein to cause disintegration of the microfilament skeleton, so that copper death is induced. The compound disclosed by the invention can be used as a potential lead compound for inducing endogenous copper ion mediated copper death for anti-tumor therapy.

To provide safe and effective compositions and methods for enhancing the efficacy and / or reducing the side effects of cancer chemotherapy and increasing the sensitivity of chemotherapy-resistant cancer cells.SOLUTION: Nutritional supplements comprising fish oil and selenium have been found to provide various activities that are beneficial in treating cancer and related conditions. The supplement provides a synergistic effect in reducing cancer cell growth when used in combination with a chemotherapeutic agent and can reduce growth in drug resistant cancer cells when used in combination with a chemotherapeutic agent to which the cells are resistant. Effects in reducing angiogenesis, reducing metastasis, decreasing the number of circulating cancer cells, and altering AXL signaling have also been found. The use of the supplement was found to reduce the wasting associated with cachexia and decrease circulating cytokines associated with inflammation. The overall effect was found to prolong survival in a clinical study.SELECTED DRAWING: Figure 1

Various embodiments of the present invention provide compositions of tumor-infiltrating lymphocytes (TILs) enriched with tumor-reactive cells. The embodiments also provide methods for producing tumor-reactive TILs enriched with tumor-reactive cells, and the use of the provided enriched tumor-reactive TILs for treating cancer in humans or other subjects. According to the embodiments, a tumor-reactive T cell enriched pharmaceutical T lymphocyte infiltration (TIL) composition comprises an oligoclonal population of tumor-infiltrating T cells, including tumor-derived CD4+ and CD8+ T cells, with up to 40 clones constituting 40% of the TCR frequency in the population. Embodiments of the present invention are particularly useful for treating tumors that are resistant or refractory to conventional chemotherapy, or that have become resistant or refractory.

The invention is based on in vitro transcribed or in vitro synthesized RNA compounds for a translation of tumor suppressor proteins in subjects suffering from a proliferative disease such as cancer. The invention provides the RNA compounds, as well as compositions for their delivery or administration to subjects. The invention in some embodiments provides novel avenues for treating chemotherapy resistant cancer diseases.

This application relates to the technical field of drug applications. This application discloses the use of honokiol in the preparation of a drug for treating retinoblastoma. It is discovered for the first time that honokiol has a new effect in treating retinoblastoma, can effectively inhibit the proliferation of retinoblastoma cells, and is of great significance for the development of new drugs for treating retinoblastoma. Experiments have proven that honokiol can inhibit the proliferation of RB cells by promoting apoptosis of RB cells and inducing cell cycle arrest. This application also discovers for the first time that honokiol has a significant therapeutic effect on multi-drug resistant RB cells, providing a new idea for solving the clinical problem of RB chemotherapy resistance. Experiments have proven that honokiol still maintains good sensitivity to RB drug-resistant cells, and its killing effect on RB / CBP drug-resistant cells is similar to that of RB non-drug-resistant cells.

The invention discloses application of 19-hydroxybufalin in preparation of a medicine for treating prostatic cancer, and belongs to the technical field of pharmaceutical preparations. The 19-hydroxybufalin is found to be targeted in vivo and in vitro for the first time, and the growth of prostate tumors is remarkably inhibited, so that the survival basis of tumor cells is fundamentally weakened, programmed death of the tumor cells is triggered, and tumor regression is effectively induced; a brand-new treatment approach is provided, namely, a non-classical drug target, namely HELLS, is degraded in a targeted manner, so that a new treatment choice is expected to be provided for a patient lacking existing target mutation; the provided 19-hydroxybufalin can be used for treating advanced prostate cancer, especially castration-resistant prostate cancer, and a new candidate treatment drug with great potential and a brand new treatment strategy are provided for effectively solving the problem that chemotherapy drug resistance and targeted therapy selection are limited in the castration-resistant prostate cancer at present.

The present invention discloses a chemotherapy resistance marker RAD51AP1 for diagnosing ovarian cancer resistance or evaluating prognosis in the treatment of ovarian cancer with platinum-based drugs, and its application, relating to the field of biomedicine technology. The present invention confirms through a series of experiments that high expression of RAD51AP1 is the key to causing platinum-based chemotherapy resistance in ovarian cancer patients. The expression level of RAD51AP1 is significantly upregulated in samples of ovarian cancer resistant to platinum-based chemotherapy. RAD51AP1 is expected to become a chemotherapy resistance marker for diagnosing or evaluating prognosis in the treatment of ovarian cancer with platinum-based drugs in clinical practice; RAD51AP1 knockdown can cause cancer cell apoptosis and enhance the efficacy of cisplatin, showing its potential as a chemotherapy resistance marker and a new target for targeted therapy; RAD51AP1 knockout combined with cisplatin treatment can significantly inhibit tumor growth, suggesting that RAD51AP1 may be an important target in cisplatin treatment, and new tumor treatment strategies are expected to be developed targeting this target.

The invention relates to the technical field of biological medicines, and particularly discloses application of MKKS3 as a drug resistance marker for intestinal cancer or intestinal cancer drugs. Researches show that MKKS3 shows high expression in intestinal cancer tissues and shows low expression in para-carcinoma tissues; meanwhile, the expression condition of the MKKS3 in chemotherapy drug-resistant and sensitive tissues is also detected, the result shows that the MKKS3 is remarkably highly expressed in the intestinal cancer chemotherapy drug-resistant tissues and is low in expression in the chemotherapy sensitive tissues, and most importantly, the Oxaliplatin sensitivity of intestinal cancer cells can be increased by knocking down the MKKS3. In addition, research also finds that high expression of MKKS3 is significantly related to poor prognosis of intestinal cancer patients. In conclusion, the application of the MKKS3 as the marker in preparation of an intestinal cancer detection reagent, a reagent for drug resistance or sensitivity of an intestinal cancer patient or a chemotherapy prognosis evaluation reagent of the intestinal cancer patient has important application value.

The invention discloses a chemotherapeutic drug-resistant tumor cell model as well as a construction method and application thereof. According to the construction method of the chemotherapeutic drug resistance tumor cell model, the chemotherapeutic drug resistance tumor cell model is obtained by transfecting a gene for coding a BAD mutant BADS99D to tumor cells, the BAD mutant BADS99D is a protein obtained by substituting the 99th serine Ser of a BAD protein with aspartic acid Asp, and the amino acid sequence is as shown in SEQ ID NO.1. The invention further discloses a construction method of the chemotherapeutic drug resistance tumor cell model. The phosphorylation state of a BAD gene is simulated through point mutation of a BADS99 site by a transgenic technology, so that chemotherapy drug-resistant tumor cells are constructed, and the regulation and control effects of phosphorylated BAD on the biological characteristics of drug resistance, proliferation, migration, invasion, self-renewal and the like of cancer cells are analyzed on the molecular level.

The invention discloses a compound RMY-186, a preparation method of the compound RMY-186 and application of the compound RMY-186 in drugs for treating drug-resistant tumors. The drugs further comprise chemotherapeutic drugs (including fluorouracil and oxaliplatin) which are used in a combined mode. The compound RMY-186 provided by the invention can directly promote the degradation of CAD regardless of whether mutation occurs or not. The chemotherapy effects of fluorouracil and the like are enhanced by promoting GC and CRC cell death and GSDME splitting decomposition. In conclusion, the RMY-186 can be used as a drug and a lead compound for overcoming GC and CRC chemotherapy drug-resistant tumors caused by CAD cleavage site mutation.

The invention discloses a gastric cancer drug-resistant animal model with clinical chemotherapy drug resistance and a construction method of the gastric cancer drug-resistant animal model. The model is characterized in that the model carries Cldn18-CreERT2; apcfl / fl; trp 53fl / fl; the method comprises the following steps: hybridizing a gastric cancer spontaneous tumorigenesis transgenic mouse of KrasG12D (Cldn18-ATK) with a CadD1371A / D1371A gene knock-in mouse, so as to obtain a Cldn18-ATK CadD1371A / D1371A double gene edited mouse; experiments show that the tumor volume reduction degree of the model after 5-FU chemotherapy is obviously lower than that of a control group (Cad + / +), and the proliferative activity (Ki-67 level) and the lifetime prolonging effect are also obviously weakened, so that the model simulates the clinical chemotherapy drug resistance phenotype. The model provides an efficient tool for gastric cancer drug resistance mechanism research and chemotherapy drug screening, and has important application value.

The invention is applicable to the technical field of biological medicines, and provides application of 20 (S)-protopanaxatriol in preparation of a medicine for reversing chemotherapy resistance of liver cancer. The invention provides application of 20 (S)-protopanaxatriol (20 (S)-protopanaxatriol, hereinafter referred to as 20S-PPT) which is derived from ginseng in preparation of drugs for reversing chemotherapy resistance of liver cancer, the sensitivity of liver cancer cells to chemotherapy drugs is improved, the chemotherapy-induced apoptosis effect is enhanced, and the in-vivo anti-tumor effect is improved on the premise that safety is guaranteed.

The application discloses a gene for treating AKT / mTOR signal path related diseases. The application proves through experiments that FAM64A promotes proliferation, invasion, lipid droplet formation and chemotherapy resistance of colorectal cancer through the Akt / mTOR signal path. Up-regulation of FAM64A expression is closely related to occurrence and subsequent development of the colorectal cancer. Abnormal expression of FAM64A can be used as an index of invasive behavior and poor prognosis of the colorectal cancer. The finding provides a new direction for treatment and drug resistance of the Akt / mTOR signal path related diseases, especially treatment and drug resistance of the colorectal cancer.

The application discloses a monomer compound DTA and application thereof in preparation of a temozolomide-sensitive glioma inhibiting drug. Through a glioma primary cell model, it is proved that the monomer compound Demethylenedelcoine A (DTA) can produce a better anti-chemotherapy resistant glioma effect than a clinical first-line chemotherapy drug temozolomide and carmustine. Therefore, in clinical treatment of temozolomide chemotherapy resistance and radiotherapy failure recurrent glioma, the monomer compound DTA can have a potential treatment advantage, and therefore has a potential drug development value.

This invention discloses a method, system, and apparatus for computer-aided drug screening based on temozolomide and ADAMTS1. This application is the first to discover that ADAMTS1 is significantly enriched in recurrent gliomas following temozolomide exposure; temozolomide strongly induces a stable senescence program, leading to excessive secretion of ADAMTS1. This senescence-induced protease coordinates significant changes in extracellular matrix composition. The remodeled microenvironment acts as a mechanobiochemical signaling agent, recruiting and polarizing host-derived myeloid cells to transform into the immunosuppressive M2 phenotype, thereby conferring chemotherapy resistance to residual glioma cells through paracrine signaling. This application reveals that the "senescence-ADAMTS1-ECM-M2" axis is a key non-cellular autonomous mechanism of temozolomide resistance. Targeting ADAMTS1-mediated matrix reprogramming can eliminate the immunosuppressive niche in gliomas and overcome chemotherapy resistance, showing broad application prospects.